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ABSTRACT
Introduction: Femoroacetabular impingement (FAI)
syndrome is a recognised cause of young adult hip
pain. There has been a large increase in the number of
patients undergoing arthroscopic surgery for FAI;
however, a recent Cochrane review highlighted that
there are no randomised controlled trials (RCTs)
evaluating treatment effectiveness. We aim to compare
the clinical and cost-effectiveness of arthroscopic
surgery versus best conservative care for patients with
FAI syndrome.
Methods: We will conduct a multicentre, pragmatic,
assessor-blinded, two parallel arm, RCT comparing
arthroscopic surgery to physiotherapy-led best
conservative care. 24 hospitals treating NHS patients
will recruit 344 patients over a 26-month recruitment
period. Symptomatic adults with radiographic signs of
FAI morphology who are considered suitable for
arthroscopic surgery by their surgeon will be eligible.
Patients will be excluded if they have radiographic
evidence of osteoarthritis, previous significant hip
pathology or previous shape changing surgery.
Participants will be allocated in a ratio of 1:1 to receive
arthroscopic surgery or conservative care.
Recruitment will be monitored and supported by
qualitative intervention to optimise informed consent
and recruitment. The primary outcome will be pain and
function assessed by the international hip outcome
tool 33 (iHOT-33) measured 1-year following
randomisation. Secondary outcomes include
general health (short form 12), quality of life (EQ5D-
5L) and patient satisfaction. The primary analysis will
compare change in pain and function (iHOT-33) at
12 months between the treatment groups, on an
intention-to-treat basis, presented as the mean
difference between the trial groups with 95% CIs. The
study is funded by the Health Technology Assessment
Programme (13/103/02).
Ethics and dissemination: Ethical approval is
granted by the Edgbaston Research Ethics committee
(14/WM/0124). The results will be disseminated
through open access peer-reviewed publications,
including Health Technology Assessment, and
presented at relevant conferences.
Trial registration number: ISRCTN64081839;
Pre-results.
BACKGROUND
Until recently, there was little understanding of
the causes of hip pain in young adults. Since
ﬁrst described in 2003, there has been increas-
ing recognition of the syndrome of femoroace-
tabular impingement (FAI), which seems to
account for a proportion of the previously
undiagnosed cases of hip pain in young
adults.1 2 Subtle deformities of hip shape
combine to cause premature contact between
the femoral neck and the acetabular rim which
may result in hip pain.1 3 These shape abnor-
malities typically divide into three categories:3 4
▸ Cam-type, in which the femoral head is
oval rather than round, or there is bony
prominence on the femoral neck;
▸ Pincer-type, in which the rim of the acet-
abulum is excessively prominent, in one
or more areas of its circumference;
Strengths and limitations of this study
▪ This trial is multicentre, pragmatic and rando-
mised, making results generalisable across the
NHS.
▪ Further strengths include a large sample size and
the robust procedures to assess treatment
fidelity.
▪ The trial has a large sample size (344).
▪ There are robust procedures to assess treatment
fidelity.
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▸ Mixed-type hip impingement, a combination of cam
and pincer types.
Surgery can be performed to reshape the bony
contour of the proximal femur and/or acetabular rim in
order to prevent impingement. Surgery for FAI has
evolved more quickly than our understanding of the epi-
demiology or natural history of the condition,5 6 and is
becoming an established treatment for FAI.7 The risks of
complications from open surgery are greater than those
for arthroscopic surgery and current evidence suggests
that the outcomes of arthroscopic treatment for the
symptoms of FAI are comparable to open surgery.8 9
Consequently, hip arthroscopy for FAI is a rapidly
growing new cost pressure for health providers.10
However, a recently published Cochrane review high-
lighted the absence of randomised controlled trials
(RCTs) comparing FAI surgery with conservative care
such as physiotherapist-led exercise.11
Physiotherapy has also been shown to be beneﬁcial
in patients with FAI syndrome.12 13 During a successful
feasibility study (HTA 10/41/02), a programme of
physiotherapist-led conservative care was developed
called personalised hip therapy (PHT).14
Aims of trial
We aim to compare the clinical and cost-effectiveness of
arthroscopic surgery versus physiotherapist-led conservative
care (PHT) in patients with symptoms of FAI syndrome.
METHODS/DESIGN
This trial will be conducted in accordance with the
Medical Research Council’s Good Clinical Practice prin-
ciples and guidelines, the Declaration of Helsinki,
Warwick Clinical Trials Unit (WCTU) standard operat-
ing procedures (SOPs), relevant UK legislation and the
trial protocol. Ethical approval was granted on 1 May
2014 (14/WM/0124), by the Edgbaston Research Ethics
committee (current approved protocol V.3.1 20/01/
2016). The trial will be reported in line with the
CONSORT statement. This full trial follows a successful
feasibility and pilot trial (HTA10/41/02).14
Trial design and setting
This is a protocol for the full UK RCT of arthroscopic
surgery for hip impingement versus best conservative
care (FASHIoN). We will conduct a multicentre, prag-
matic, assessor-blinded, parallel arm, 12 months, 1:1 RCT
of hip arthroscopy versus conservative care for FAI asses-
sing patient pain, function, general health, quality of life,
satisfaction and cost-effectiveness. There is an integrated
qualitative recruitment intervention that includes inter-
views with recruiters and patients, and observations of
recruitment appointments to ensure patients have the
opportunity to fully consider participation in the trial.15
We hypothesise that arthroscopic surgery is superior to
conservative care at 12 months for self-reported hip pain
and function for patients with FAI syndrome. The trial
will be conducted on consenting patients treated in the
NHS. Hospitals participating in FASHIoN will have an
organised hip arthroscopy service treating at least 20
patients with arthroscopic surgery for FAI per year.
Target population
We intend to recruit a cohort of typical patients with FAI
deemed suitable for arthroscopic surgery. This included
patients who may have already received a course of
physiotherapy.
Inclusion criteria
▸ Age ≥16 (no upper age limit);
▸ Symptoms of hip pain—patients may also have symp-
toms of clicking, catching or giving way;
▸ Radiographic evidence of pincer- and/or cam-type
FAI morphology on plain radiographs and cross-
sectional imaging, deﬁned as:
– Cam morphology—an α angle >55°;16
– Pincer morphology—a lateral centre edge angle of
>40° or a crossover sign on the anteroposterior
radiograph of the pelvis;17
The treating surgeon believes the patient would beneﬁt
from arthroscopic FAI surgery;
The patient is able to give written informed consent and
to participate fully in the interventions and follow-up
procedures.
Exclusion criteria
▸ Evidence of pre-existing osteoarthritis, deﬁned as
Tonnis grade >1,18 or more than 2 mm loss of super-
ior joint space width on anterio-posterior pelvic
radiograph;19
▸ Previous signiﬁcant hip pathology such as Perthes’
disease, slipped upper femoral epiphysis or avascular
necrosis;
▸ Previous hip injury such as acetabular fracture, hip
dislocation or femoral neck fracture;
▸ Previous shape changing surgery (open or arthro-
scopic) in the hip being considered for treatment.
Participant identification, invitation, recruitment and
baseline data collection
Patients who complain of hip pain, who do not already
have a diagnosis of hip osteoarthritis, will be identiﬁed
as potential participants by screening referral letters to
collaborating surgeons. Research nurses/associates will
keep accurate screening logs to identify if these potential
participants meet the eligibility criteria. Once diagnosed
with FAI syndrome by the surgeon, and deemed eligible
for the trial, the patient will be given a trial information
sheet (see online supplementary ﬁles 1 and 2) and
referred to a trained recruiter for a trial information
consultation. During this consultation, patients can
discuss the trial, participation will be offered and
informed consent obtained (see online supplementary
ﬁles 3 and 4). It will be explained that participation is
voluntary and patients can withdraw at any time. Once
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consent is obtained, and prior to treatment allocation,
baseline patient reported outcomes will be collected
(see the Outcome measures section).
In order to optimise recruitment and informed
consent, trained qualitative researchers will observe
recordings of the surgeons’ and research associate/
nurses’ trial information consultations (see online sup-
plementary ﬁles 2 and 4), to identify communication
patterns that facilitate or hinder patient recruit-
ment15 (see ﬁgure 1). In-depth interview with the recrui-
ters will be undertaken to identify clear obstacles and
hidden challenges to recruitment, including the inﬂu-
ence of patient preferences and equipoise.20 Research
teams will be interviewed to identify clinician equipoise,
patient pathway from eligibility to consent and staff
training needs at each participating site.15 Findings will
be fed back to the CI and trial management group, so
that practice can be reviewed and any necessary changes
(including additional training) implemented. The
number of eligible patients, the percentages of these
that are approached and consented to be randomised
will be monitored at each site.
This research will be linked, through Donovan, to the
Quintet programme of research within the MRC
ConDuCT-II (Bristol) Trial Methodology Hub.
Randomisation
Participants will be randomised, in a 1:1 ratio, to arthro-
scopic surgery or PHT using a computer-generated
sequence. Allocation will be made by the research
nurse/associate via a centralised telephone randomisa-
tion service provided remotely by WCTU. Allocation
concealment will be ensured, as the randomisation pro-
gramme will not release the randomisation code until
the patient has been recruited into the trial. In order to
improve baseline balance between intervention group
samples, a minimisation (adaptive stratiﬁed sampling)
algorithm will be implemented using study site and
impingement type (cam, pincer or mixed) factors.
Research nurses/associates who recruit participants will
ensure they are referred for the allocated intervention.
Patients and clinicians cannot be blind to treatment allo-
cation. However, outcome assessors will be blind to the
treatment delivered.
Interventions
The two interventions will start as soon as possible after
randomisation. We will record dates of randomisation
and the start of allocated treatment. As this is a prag-
matic trial, participants were not prohibited from under-
going any additional/concomitant care.
Arthroscopic surgery
Arthroscopic surgery will be completed by a Consultant
Surgeon delivering hip arthroscopy as part of their
routine practice. Arthroscopic hip surgery will be per-
formed under general anaesthesia according to the sur-
geon’s usual practice. Shape abnormalities and
consequent labral and cartilage pathology will be
treated. Bony resection at the acetabular rim and at the
head–neck junction will be assessed by intraoperative
image intensiﬁer radiographs and/or satisfactory
impingement-free range of movement of the hip.
Patients will be allowed home when they can walk safely
with crutches (usually within 24 hours). On discharge,
patients will be referred for a course of rehabilitation as
per usual care for that surgeon. We will not specify a
protocol for this postoperative physiotherapy, but will
record the surgeons’ routine postop care and any
case-by-case changes to this. Care will be taken to ensure
that physiotherapists delivering postoperative care to
FASHIoN trial participants are different from those
trained and providing PHT in order to avoid contamin-
ation between groups. Patients will also have a post-
operative MRI after 6 weeks.
In order to ensure the ﬁdelity of the surgery and to
identify participants for a secondary analysis, a panel of
international experts will review operation notes, intrao-
perative images and postoperative MRI scans to assess
whether adequate surgery was undertaken. This panelFigure 1 Participant flow diagram.
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includes: Mark Philippon (USA), Martin Beck
(Switzerland), John O’Donnell (Australia) and Professor
CEH (UK).
Personalised hip therapy
PHT is a package of physiotherapist-led best conservative
care for FAI. It was developed during the feasibility study
and ‘road-tested’ during the pilot trial (HTA 10/41/
02).14 The care being offered represents a consensus of
what physiotherapists, physicians and surgeons regard as
‘best conservative care’ for FAI. PHT will be delivered by
a senior physiotherapist at each site, who will be trained
at a FASHIoN PHT workshop, and supported in PHT
delivery by a physiotherapy research facilitator.
PHT consists of four key components:
1. An assessment of pain, function and range of hip
motion,
2. Patient education and advice,
3. Help with pain relief (which may include up to one
radiographic-guided intra-articular steroid injection
where pain prevents performance of the exercise
programme),
4. An exercise programme that has the key features of
individualisation, progression and supervision.
The intervention is delivered over a minimum of six
patient contacts (at least three of which must be
face-to-face treatment contacts, others can be by tele-
phone and email) over a period of 6 months. In situa-
tions where the patient needs additional review, support
or guidance, further sessions with the physiotherapist are
permitted up to a maximum of 10 contacts. Evidence of
exercise individualisation, supervision and progression
will be sought from individual participant physiotherapy
case report forms (CRFs). Accuracy of CRFs will be
audited against the physiotherapist’s treatment notes.
The PHT CRFs will be assessed for intervention
ﬁdelity to identify participants for a secondary analysis
by the panel that developed the protocol for PHT,
including: Professor NEF (Senior Academic Research
Physiotherapist), Ivor Hughes and David Robinson (UK;
Extended Scope Musculoskeletal Physiotherapists) and
PW (Academic Orthopaedic Surgeon).
Crossover of participants between interventions can be
problematic in trials of this nature. In order to minim-
ise, this care will be taken prior to enrolment in the trial
to ensure potential participants:
▸ Are willing to receive either intervention,
▸ Understand both treatments are thought to provide
beneﬁt,
▸ Are willing to remain with their allocation for
12 months,
▸ Understand that both interventions may take
6 months to improve symptoms.12 19
In instances where patients are not satisﬁed with how
their treatment is progressing prior to reaching the
primary outcome, they will be able to have a further con-
sultation with their treating surgeon where they would
be treated in their best interests.
Risks and benefits
Both interventions are thought to provide beneﬁt in
patients with FAI. The short-term risks of this study
relate to the two interventions. These risks are described
below and inform the expected serious adverse events
(SAEs).
Hip arthroscopy requires a general anaesthetic. The
risk of complications from hip arthroscopy is about
1–2%. These include:
▸ Infection—thought to be <1 in 1000.
▸ Bleeding—possibly causing bruising or a local
haematoma.
▸ Traction-related—in order to perform hip arthros-
copy, traction is required to separate the hip joint sur-
faces. Sometimes after the procedure, the pressure
from the traction can cause some numbness in the
leg. The numbness usually resolves within a few hours
or days.
▸ Osteonecrosis—during surgery, the blood supply to
the hip joint could be damaged. However, there are
no reported cases of osteonecrosis following arthro-
scopic FAI surgery.
▸ Femoral neck fractures—this is also a very rare com-
plication. This complication would require a further
procedure to ﬁx the fracture.
Personalised hip therapy
There are some small risks with pain medications and
joint injection. However, the main risk is muscle soreness
and transient increases in pain from the exercises that
will be undertaken.
Outcome measures
Baseline data will be collected from participants once
consent is obtained and prior to randomisation.
Table 1 Data collection time points
Time point Data collection
Baseline Demographics, physical activity
(UCLA Activity Scale),29 iHOT-33,
SF-12,EQ-5D
Preoperative imaging, economics
questionnaire
Intervention Operation notes and photographs;
or PHT log. Complications records
6 weeks post start of intervention.
Postoperative MRI (surgery
intervention only)
6 months iHOT-33, SF-12, EQ-5D, resource
usage, adverse events
12 months (primary
outcome)
iHOT-33, SF-12, EQ-5D, patient
satisfaction, resource usage,
adverse events
2 years Further procedures questionnaire
3 years Further procedures questionnaire
5 and 10 years Linkage to National Joint Registry
and HES to identify need for hip
replacement
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Follow-up questionnaires will be administered centrally
by a data clerk via post. If participants fail to respond,
they will be contacted via telephone, email or via their
next of kin where necessary. Table 1 lists the data col-
lected and at which follow-up time points.
Primary outcome
The primary outcome measure is hip pain, function and
hip-related quality of life using the International Hip
Outcome Tool-33 (iHOT-33) at 12 months following ran-
domisation. iHOT-33 is a validated hip-speciﬁc patient-
reported outcome tool which measures health-related
quality of life in young, active patients with hip disor-
ders.21 It consists of the following domains: symptoms
and functional limitations, sports and recreational activ-
ities, job-related concerns and social, emotional and life-
style concerns.
We chose it following our feasibility and pilot study as:
▸ It is more sensitive to change than other hip outcome
tools,21
▸ It does not show evidence of ﬂoor or ceiling effects
in patients undergoing hip arthroscopy,21
▸ Patients were involved extensively in item generation;
so we can be conﬁdent that it measures what is most
important to patients,21
▸ There is an independently determined minimally
clinically important difference (MCID),21
▸ It is used as the principal outcome measure for the
UK Non-Arthritic Hip Registry; mandated for arthro-
scopic FAI surgery by the National Institute of Health
and Care Excellence (NICE).10
Secondary outcome measures
Health-related quality of life: EQ-5D 5L
This is a validated measure of health-related quality of
life, consisting of a ﬁve-dimensional health status classiﬁ-
cation system and a separate visual analogue scale.
EQ-5D is applicable to a wide range of health conditions
and treatments and provides a simple descriptive proﬁle
and a single index value for health status.22 Responses
will be converted into health utility scores using estab-
lished algorithms.23
General health: Short Form-12 Health Survey V.2
This is a validated and widely used health-related
quality-of-life measure, particularly including hip condi-
tions and treatments.24 SF-12 is able to produce the
physical and mental component scales originally devel-
oped from the SF-36 with considerable accuracy but with
far less respondent burden.25 Responses will be con-
verted into health utility scores using established
algorithms.26
Patient satisfaction
Using questions that our team (Foster) has used in previ-
ous trials with musculoskeletal pain patients,27 we will
measure two distinct dimensions of satisfaction in all par-
ticipants during follow-up: ‘Overall, how satisﬁed are you
with the treatment you received?’ and ‘Overall, how satisﬁed are
you with the results of your treatment?’ Responses are on a
5-point Likert scale. These questions are in line with pre-
vious studies of patient satisfaction which show that the
majority of patients express overall satisfaction with the
care they received, but fewer express overall satisfaction
with the clinical outcomes resulting from their care.
Qualitative assessment of outcome
We will conduct in-depth interviews one-to-one with a
purposively selected sample of 25–30 participants in
each of the trial groups, including older and younger,
male and female, more and less active and more and
less satisﬁed participants recruited at different trial sites.
The qualitative interviews will supplement the quantita-
tive outcomes. Interviews will explore experiences of the
trial processes, the treatments and the consequences of
treatment to participants’ lives, health and well-being.
Adverse events
We will record the number and type of adverse events
(AEs) up to 12 months. Any AEs will be reported on the
appropriate CRF and returned to WCTU. Any SAEs will
be faxed to WCTU, within 24 hours of the local investi-
gator becoming aware, where the Chief Investigator will
determine causality and expectedness. SAEs deemed
unexpected and related to the trial will be reported to
the research ethics committee within 15 days.
Resource usage
Information on healthcare resource use will be collected by
incorporating questions within the patient follow-up ques-
tionnaires. We conﬁrmed the feasibility and acceptability of
this approach in our pilot trial, and patient self-reported
information on service use has been shown to be accurate
in terms of the intensity of use of different services.28
Need for further procedures
We will record any further treatments performed in
both groups, such as hip arthroscopy, open hip preserva-
tion surgery, hip replacement or additional ‘out of trial’
physiotherapy. We propose to ascertain the need for
further procedures by questionnaire at 2 and 3 years. We
also propose a 5 and 10-year no-cost ascertainment of
hip replacement by linkage to the UK National Joint
Registry (NJR) and Hospital Episode Statistic (HES)
databases.
Sample size calculation
The development work for iHOT-33 reported a mean
iHOT-33 score of 66 and an SD of 19.3 in a heteroge-
neous population with a variety of hip pathologies. The
baseline iHOT-33 data from our pilot trial (HTA grant
10/41/02) suggests the target population of patients
being considered for hip arthroscopy for FAI have lower
scores with less variability, with a mean of 33 and SD of
16. The MCID for iHOT-33 in this population is 6.1
points.21
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Our sample size calculation is therefore based on an
SD of 16 and a between-group MCID of 6.1: a standar-
dised effect difference between groups at 12 months of
0.38. The expected sample size for 90% power to detect
an effect size of 0.38 at 12 months, at a 5% signiﬁcance
level, assuming an approximately normal distribution of
the iHOT-33 score is 292. Allowing for 15% loss to
follow-up at 12 months, we will recruit a sample of 344
participants over 26months in the UK (172 in each
group).
Statistical analysis
The primary analysis will be of differences in hip-related
quality of life (iHOT-33) at 12 months between the two
treatment groups, blinded, on an intention-to-treat basis
and presented as the mean difference between the trial
groups with a 95% CI. iHOT-33 data will be assumed to
be normally distributed; possibly after appropriate
variance-stabilising transformation.
The minimisation randomisation procedure should
ensure treatment group balance across recruiting sites.
We have no reason to expect that clustering effects will
be important for this study, but the possibility of such
effects will be explored as part of the analysis.33 We plan
to account for clustering by generalising a conventional
linear (ﬁxed-effects) regression approach to a
mixed-effects modelling approach; where patients are
naturally grouped by recruiting sites (random-effects)
and, if amenable to analysis, also by physiotherapist and
surgeon. This model will formally incorporate terms that
allow for possible heterogeneity in responses for patients
due to the recruiting centre, in addition to the ﬁxed
effects of the treatment groups, and patient character-
istics that may prove to be important moderators of treat-
ment effect such as age, gender and FAI type. This
analysis will be conducted using specialist mixed-effects
modelling functions available in the software packages
Stata (StataCorp. 2015. Stata Statistical Software: Release
14. College Station, Texas, USA: StataCorp LP) and R
(http://www.r-project.org/). All tests will be two-sided
and considered to provide evidence for a statistically sig-
niﬁcant difference if p values are <0.05 (5% signiﬁcance
level).
Secondary analyses will be performed using the above
strategy for other approximately normally distributed
outcome measures, including iHOT-33 at 6 months,
SF-12 (and computed subscales) and EQ5D. Differences
in dichotomous outcome variables such as AEs, compli-
cations related to the trial interventions and the need
for further procedures will compared between groups
using χ2 tests (or Fisher’s exact test) and mixed-effects
logistic regression analysis will be undertaken, adjusting
for the stratifying variables, with differences between
trial intervention groups quantiﬁed as ORs (and 95%
CIs). The temporal patterns of any AEs will be presented
graphically and if appropriate, a time-to-event analysis
(Kaplan-Meier survival analysis) will be used to assess
the overall risk and risk within individual classes of AEs.
Ordinal scores for patient satisfaction will be compared
between intervention groups using proportional odds
logistic regression analysis, assuming that the estimated
intervention effect between any pair of categories is
equivalent.
Our inferences will be drawn from the intention-
to-treat analysis. We will perform two exploratory
secondary analyses. One will compare patients who
received surgery and those who received conservative
care. A second exploratory analysis will compare patients
randomised to surgery or PHT and received treatment
deemed to be of a high ﬁdelity by the respective review
panels. We plan to perform a subgroup analysis by FAI
type because it is possible that treatment effect is moder-
ated by type. We anticipate that adequate steps have
been taken to prevent crossovers from being a major
issue for this study. Therefore, we expect the main
intention-to-treat analysis to provide deﬁnitive results. An
independent Data Monitoring Committee (DMC) will
monitor crossovers and adherence to treatment and
advise on appropriate modiﬁcations to the statistical ana-
lysis plan as the full trial progresses.
The initial feasibility and pilot studies (HTA 10/41/
02) were designed explicitly to assess feasibility and
measure recruitment rates, and not to estimate treat-
ment effectiveness. Data from the pilot will be pooled
with data from the full trial, and analysed together.
Economic analysis
An economic evaluation will be integrated into the trial
design and will be conducted from the recommended
NHS and personal social services perspective.30
Cost-effectiveness will be calculated using both within
trial and lifetime horizons. Data will be collected on the
health and social service resources used in the treatment
of each trial participant until 12 months.
An incremental cost-effectiveness analysis, expressed
in terms of incremental cost per quality-adjusted life
year gained, will be performed. Results will be presented
using incremental cost-effectiveness ratios and cost-
effectiveness acceptability curves generated via non-
parametric bootstrapping.
Qualitative interview analysis
Participant interview transcripts will be analysed themat-
ically, using methods of constant comparison derived
from grounded theory.31 Emerging themes will be
explored, looking for shared or disparate views among
patients about their experiences, and among clinicians
about their experiences of delivering the trial interven-
tions. Focused conversation analysis will be undertaken
on sections of recruitment appointments, and compared
with the six-step good recruitment model developed in
the pilot study to identify aspects of RCT presentation
that are unclear, disrupted or hinder recruitment.15 20 32
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Data management
All of the data collected in this trial will be entered into
a secure trial database held at WCTU. All data collected
will be anonymised after the collection of baseline
demographic data, and all participants given a unique
trial number. Identiﬁable participant data will be held in
a locked ﬁling cabinet and coded with a trial participant
number to tag identiﬁable data to the outcome data.
The WCTU quality assurance manager will undertake
audits of trial records in accordance with WCTU SOPs.
A DMC will be established comprised of members who
are independent of the sponsor and who do not have
competing interests. The DMC will review trial progress,
interim data and safety aspects of the trial. They will also
review the statistical analysis plan. Any recommendations
will be fed back to the trial steering committee (TSC) by
the DMC chair. Outcomes will not be analysed until all
primary outcome data are collected. The trial may be
stopped prematurely if mandated by the research ethics
committee, the DMC or if funding ceases.
DISCUSSION
This protocol paper describes the FASHIoN trial; a mul-
ticentre RCT comparing hip arthroscopy to best conser-
vative care (PHT) in order to establish the most
clinically and cost-effective treatment for patients with
FAI syndrome. Further details of the trial protocol can
be found on the ISRCTN registry (ISRCTN64081839).
This protocol will also be used for a randomised trial in
Australia (ACTRN12615001177549). The results of the
trial will be disseminated at international meetings and
in peer-reviewed journals; to participants via post and to
the public via the trial website.
The main strengths of this trial are that it is multicentre,
pragmatic and randomised, making results generalisable
across the NHS. Further strengths include a large sample
size and the robust procedures to assess treatment ﬁdelity.
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